Pharmaceuticals News and Research

RSS

BioSante signs Option Agreement to obtain non-exclusive worldwide license for 2A/Furin technology

BioSante Pharmaceuticals, Inc. today announced that it has entered into an Option Agreement with an undisclosed large multi-national pharmaceutical company to obtain a non-exclusive worldwide license for the use of BioSante's 2A/Furin technology in the expression of antibodies.

26 Apr 2010

Covidien introduces PENNSAID to the U.S. market

Covidien, a leading global provider of healthcare products, has introduced PENNSAID (diclofenac sodium topical solution) 1.5% w/w to the U.S. market. PENNSAID is the only FDA-approved topical non-steroidal anti-inflammatory drug in a vehicle solution containing dimethyl sulfoxide, a known penetrating agent. It is indicated for treatment of the signs and symptoms of osteoarthritis of the knee(s).

26 Apr 2010

Covidien launches EXALGO Extended-Release Tablets in the US

Covidien, a leading global provider of healthcare products, today introduced EXALGO™ (hydromorphone HCI) Extended-Release Tablets, (CII), the only extended-release hydromorphone treatment available in the United States. This proven therapy, combined with an innovative delivery system, provides opioid-tolerant patients suffering from moderate-to-severe chronic pain relief for 24 hours per dose.

26 Apr 2010

First Edition: April 26, 2010

Today's headlines reflect state-level health policy developments as well as forward-looking stories related to the cost of federal health reforms.

26 Apr 2010

Napo Pharmaceuticals announces formation of Finder's Agreement with Luye Pharma Group

Napo Pharmaceuticals, Inc., which focuses on the development and commercialization of proprietary pharmaceuticals for the treatment of diarrheal diseases in the global marketplace in collaboration with local partners, is pleased to announce the formation of a Finder's Agreement with its licensee for crofelemer in China, Luye Pharma Group Ltd. (formerly Asiapharm).

26 Apr 2010

MicroStockProfit.com releases investment report on Rexahn Pharmaceuticals

MicroStockProfit.com announces an investment report featuring Rexahn Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

26 Apr 2010

Ness Technologies announces implementation of Oracle E-Business Suite at Teva Czech Industries

Ness Technologies, Inc., a global provider of information technology solutions and services, announced today the start of an Oracle E-Business Suite implementation at Teva Czech Industries s.r.o., a provider of pharmaceutical products. The new system will handle financial and logistics issues, replacing a current QAD MFG/Pro system.

26 Apr 2010

Anacor Pharmaceuticals, MMV partner to discover and develop promising new malaria therapeutics

Anacor Pharmaceuticals today announced that it has entered into a research agreement with not-for-profit Medicines for Malaria Venture (MMV) to explore Anacor's novel boron chemistry platform for developing new therapeutics for the treatment of malaria. Under the agreement, Anacor will be responsible for leading the research effort and MMV will contribute its extensive malaria drug research expertise as well as financial support.

26 Apr 2010

Biotage to acquire MIP Technologies

Biotage AB a global leader in tools and technology for medicinal and analytical chemistry, and the owners of MIP Technologies AB today announced that the parties have signed a definitive agreement under which Biotage will acquire all outstanding shares in MIP Technologies, a privately held leading developer of molecularly imprinted polymers (MIPs) and other novel polymers.

26 Apr 2010

Ballan wrasse for combating sea lice

The sea lice parasite is the greatest disease problem facing the Norwegian aquaculture industry. But help may be on its way - an army of 15 million lice-eating Ballan wrasse.

26 Apr 2010

Charles River Laboratories International, WuXi PharmaTech sign definitive agreement to combine

Charles River Laboratories International, Inc., a leading global provider of research models and associated services and of preclinical drug development services, and WuXi PharmaTech, a leading drug research and development outsourcing company with expertise in discovery chemistry and with operations in China and the United States, today announced that they have signed a definitive agreement under which Charles River and WuXi will combine in a cash and stock transaction valued at approximately $1.6 billion.

26 Apr 2010

Charles River Laboratories International reports 1.4% decline in first-quarter 2010 net sales

Charles River Laboratories International, Inc. today reported its results for the first quarter of 2010. For the quarter, net sales were $297.3 million, a decline of 1.4% from $301.5 million in the first quarter of 2009. The decrease was net of a foreign currency translation benefit of 3.4%. Higher sales for the Research Models and Services (RMS) segment were offset by lower sales for the Preclinical Services (PCS) segment.

26 Apr 2010

WCRI study finds cost per claim for prescription drugs to treat injured workers in Maryland higher

The cost per claim for prescription drugs used to treat injured workers in Maryland was slightly higher than in most study states in a new study by the Workers Compensation Research Institute (WCRI).

26 Apr 2010

Targeted therapy based on molecular signatures for treating lung cancer

The first lung cancer clinical trial to guide targeted therapies to patients based on molecular signatures in tumor biopsies is a step toward personalized care and more effective, efficient clinical trials for new drugs, study leaders reported today during the American Association for Cancer Research 101st Annual Meeting 2010.

24 Apr 2010

Recent business progress at Penwest Pharmaceuticals

Penwest Pharmaceuticals Co. today sent a letter to its shareholders to provide an update on the Company's recent progress and on corporate governance developments.

24 Apr 2010

Physician panel to discuss issues related to Qutenza at Investor Day

NeurogesX, Inc., a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that Anthony DiTonno, President and CEO, and members of the NeurogesX management team, will host an Investor Day on Friday, April 30, 2010, from 8:15am-11:00am EDT in New York City

24 Apr 2010

2010 Aggregate Spend and Disclosure Reporting Industry Survey of compliance program experts

Cegedim Dendrite today announced the results of the 2010 Aggregate Spend and Disclosure Reporting Industry Survey of compliance program experts from Life Sciences companies. Cegedim Dendrite is the leading provider of Customer Relationship Management, Regulatory Compliance, Data Optimization and Marketing solutions designed specifically for the Life Sciences industry.

24 Apr 2010

New research project to make anti-malarial drugs more affordable in Third World countries

Dr Geoff Brown, from the University of Reading's Department of Chemistry, is beginning a £400,000 project that could prove vital for the developing world in its ongoing fight against malaria. His research aims to make anti-malarial drugs more affordable in Third World countries where more than 1.5 million people die of the disease every year.

24 Apr 2010

CPEX recommends shareholders to take no action on Arcadia's unsolicited tender offer

The Board of Directors of CPEX Pharmaceuticals Inc., today recommended that its shareholders take no action at this time in response to the announcement by Arcadia Capital Advisors, LLC through RSR Acquisition Co. and its principal Richard Rofé that it has made an unsolicited conditional tender offer to acquire all of the outstanding shares of CPEX for $16.00 per share in cash.

24 Apr 2010

Trinean launches DropSense96 and DropPlate 16 G for genomic DNA quantification

Only 6 months after the release of its ground-breaking DropSense 96 spectrophotometer, Trinean, pioneer in high throughput analysis of droplets of samples in microfluidic structures, is now launching another device that will set the tone in scientific circles: the DropPlate 16 G. This upgrade of the current microfluid disposable, the DropPlate 16 U, allows researchers to quantify 96 DNA/RNA samples of only 2 microl in less than 5 minutes.

24 Apr 2010

Pharmaceuticals News and Research

BioSante signs Option Agreement to obtain non-exclusive worldwide license for 2A/Furin technology

Covidien introduces PENNSAID to the U.S. market

Covidien launches EXALGO Extended-Release Tablets in the US

First Edition: April 26, 2010

Napo Pharmaceuticals announces formation of Finder's Agreement with Luye Pharma Group

MicroStockProfit.com releases investment report on Rexahn Pharmaceuticals

Ness Technologies announces implementation of Oracle E-Business Suite at Teva Czech Industries

Anacor Pharmaceuticals, MMV partner to discover and develop promising new malaria therapeutics

Biotage to acquire MIP Technologies

Ballan wrasse for combating sea lice

Charles River Laboratories International, WuXi PharmaTech sign definitive agreement to combine

Charles River Laboratories International reports 1.4% decline in first-quarter 2010 net sales

WCRI study finds cost per claim for prescription drugs to treat injured workers in Maryland higher

Targeted therapy based on molecular signatures for treating lung cancer

Recent business progress at Penwest Pharmaceuticals

Physician panel to discuss issues related to Qutenza at Investor Day

2010 Aggregate Spend and Disclosure Reporting Industry Survey of compliance program experts

New research project to make anti-malarial drugs more affordable in Third World countries

CPEX recommends shareholders to take no action on Arcadia's unsolicited tender offer

Trinean launches DropSense96 and DropPlate 16 G for genomic DNA quantification

Oxygen Measurement eBook - Easily Understand Dissolved Oxygen Measurement eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence